Cumberland Pharmaceuticals Inc. (CPIX) Financial Statements (2024 and earlier)

Company Profile

Business Address 2525 WEST END AVENUE
NASHVILLE,, TN 37203
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments18,32218,50818,24916,38619,75819,542
Cash and cash equivalents18,32218,50818,24916,38619,75819,542
Receivables9,75812,62012,21914,52913,16415,233
Inventory, net of allowances, customer advances and progress billings4,6098,67110,92810,1809,86410,648
Inventory4,6098,67110,92810,1809,86410,648
Other current assets  1,9712,2782,715 3,739
Other undisclosed current assets3,025   3,085 
Total current assets:35,71441,77043,67443,81145,87049,161
Noncurrent Assets
Inventory, Noncurrent12,8058,3026,6947,5347,5277,497
Operating lease, right-of-use asset6,6746,7116,8324,9195,218220
Property, plant and equipment368377384355284491
Intangible assets, net (including goodwill)23,52228,03529,18430,30431,50530,981
Goodwill9149149149149141,933
Intangible assets, net (excluding goodwill)22,60827,12128,27029,39030,59129,048
Other noncurrent assets2,6932,5562,6072,5452,5212,427
Total noncurrent assets:46,06245,98145,70145,65847,05541,616
TOTAL ASSETS:81,77687,75189,37589,46992,92590,777
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14,03810,81810,91211,22228,40711,511
Accounts payable14,03810,81810,91211,22210,81911,511
Accrued liabilities     17,588 
Other liabilities13,59716,17615,72614,327 13,566
Other undisclosed current liabilities348334321158173230
Total current liabilities:27,98227,32826,95925,70728,58025,306
Noncurrent Liabilities
Long-term debt and lease obligation12,78412,92313,14816,07216,20017,700
Long-term debt, excluding current maturities12,78412,92313,14816,07216,20017,700
Liabilities, other than long-term debt11,75011,84412,43111,64012,171 
Other liabilities6,4546,4556,9547,0917,585 
Operating lease, liability5,2965,3895,4774,5494,586 
Other undisclosed noncurrent liabilities      9,279
Total noncurrent liabilities:24,53424,76725,57927,71328,37126,979
Total liabilities:52,51652,09552,53853,42056,95152,285
Equity
Equity, attributable to parent, including:29,60335,99237,15936,36136,26638,764
Common stock  47,18547,30347,377 47,532
Accumulated deficit(17,488)(11,194)(10,144)(11,017)(11,209)(8,768)
Other undisclosed equity, attributable to parent47,092   47,475 
Equity, attributable to noncontrolling interest(344)(336)(322)(312)(292)(273)
Total equity:29,26035,65636,83736,04835,97438,491
TOTAL LIABILITIES AND EQUITY:81,77687,75189,37589,46992,92590,777

Income Statement (P&L) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Revenues9,35310,08610,8899,2259,12411,413
Other income   9821,847  
Cost of revenue
(Cost of Goods and Services Sold)
(1,530)(1,766)(1,521)(1,250)(2,650)(2,224)
Gross profit:7,8238,3209,3687,9746,4739,189
Operating expenses(14,002)(10,187)(9,345)(9,506)(8,751)(9,477)
Operating income (loss):(6,179)(1,867)23(1,532)(2,278)(289)
Nonoperating income
(Investment Income, Nonoperating)
8199575065722
Interest and debt expense (179)(110)(193)(186)(179)(149)
Loss from continuing operations before equity method investments, income taxes:(6,277)(1,878)(113)(1,668)(1,800)(416)
Other undisclosed income (loss) from continuing operations before income taxes 8229821,847(611) 
Income (loss) from continuing operations before income taxes:(6,277)(1,056)869179(2,412)(416)
Income tax expense(25)(7)(7)(7)(48)(7)
Income (loss) from continuing operations:(6,302)(1,063)862172(2,460)(423)
Loss before gain (loss) on sale of properties:(423)
Net income (loss):(6,302)(1,063)862172(2,460)(423)
Net income (loss) attributable to noncontrolling interest81410201915
Net income (loss) available to common stockholders, diluted:(6,294)(1,049)872192(2,441)(409)

Comprehensive Income ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net income (loss):(6,302)(1,063)862172(2,460)(423)
Comprehensive income (loss):(6,302)(1,063)862172(2,460)(423)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest81410201915
Comprehensive income (loss), net of tax, attributable to parent:(6,294)(1,049)872192(2,441)(409)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: